"PT Global Bioray Teknologi and APIS Assay Technologies Sign Collaboration to Commercialise the ESR1 Mutations Kit & the Breast Cancer Subtyping Kit..."
3 days ago
Licensing / partnership
|
APIS Breast Cancer Subtyping Kit • APIS ESR1 Mutations Kit
"The article is titled ‘Comprehensive and Accurate Molecular Profiling of Breast Cancer through mRNA Expression of ESR1, PGR, ERBB2, MKI67, and a Novel Proliferation Signature‘ published in MDPI."
"Biocartis Group NV...announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (APIS), the APIS Breast Cancer Subtyping Kit and the APIS ESR1 Mutations Kit."
12 months ago
Licensing / partnership • Launch
|
APIS Breast Cancer Subtyping Kit • APIS ESR1 Mutations Kit • Idylla™ PIK3CA-AKT1 Mutation Assay
"Biocartis Group NV...and APIS Assay Technologies Ltd...today announced the expansion of their partnership to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis’ worldwide commercial network....'Together with the Idylla™ PIK3CA-AKT1 Mutation Assay and the APIS Breast Cancer Subtyping Kit we will be able to provide a comprehensive menu of products in the breast cancer domain to our customers.'"
"Biocartis Group NV...and APIS Assay Technologies Ltd...announce that they have entered into a new partnership agreement which targets the development of APIS’ Breast Cancer Subtyping assay on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™....Under the terms of the partnership agreement, APIS will lead the development of the Breast Cancer Subtyping test on Idylla™, while Biocartis will lead the commercialisation through its growing Idylla™ network."